Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency

PharmacoEconomics

Volumn 23, Issue 4, 2005, Pages 395-420

  Schädlich, Peter K ^a,h   Zeidler, Henning ^b   Zink, Angela ^c   Gromnica Ihle, Erika ^d   Schneider, Matthias ^e   Straub, Christoph ^f   Brecht, Josef G ^a   Huppertz, Eduard ^g  

^a InForMed GmbH Outcomes Research and Health Economics   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c German Natl Research Cent for   (Germany)

^d Arthritis Clinics Berlin Buch   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f TK Technicians' Sickfund   (Germany)

^g SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^h InForMed GmbH Outcomes Research and Health Economics   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUROTHIOMALATE; AZATHIOPRINE; CHLOROQUINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ABSENTEEISM; ARTICLE; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG THERAPY; GERMANY; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; MODEL; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; RETIREMENT; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SEQUENTIAL DRUG THERAPY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DRUG COSTS; GERMANY; HUMANS; ISOXAZOLES; MODELS, ECONOMIC; RANDOMIZED CONTROLLED TRIALS;

EID: 18744377712     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200523040-00008     Document Type: Article

References (54)

1. Zink A, Listing M, Niewerth H, et al. The national database of the German Collaborative Arthritis Centres: II. Treatment of patients with rheumatoid arthritis. Ann Rheum Dis 2001; 60: 207-13
2. Prakash A, Jarvis B. Leflunomide: a review of its use in active rheumatoid arthritis. Drugs 1999; 58: 1137-64
3. EMEA - The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products. European Public Assessment Report Arava, International Non-proprietary Name (INN) Leflunomide. London: EMEA, 2000
4. Schädlich PK, Zeidler H, Zink A, et al. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient related costs. Pharmacoeconomics 2005; 23 (4): 389-405
5. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulfasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999; 353: 259-66
6. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999; 159: 2542-50
7. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000; 39: 655-65
8. Sharp JT, Strand V, Leung H, et al. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis. Arthritis Rheum 2000; 43: 495-505
9. Strand V, Tugwell P, Bombardier C, et al. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42: 1870-8
10. Cambridge Pharma Consultancy. The Arava® interactive models. Cambridge: Cambridge Pharma Consultancy, 1999. (Data on file)
11. Choi HK, Seeger JD, Kuntz KM. A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. J Rheumatol 2002; 29: 1156-65
12. Ollendorf DA, Peterson AN, Doyle J, et al. Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population. Am J Manag Care 2002;8:5203-13
13. Maetzel A, Strand V, Tugwell P, et al. Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomised controlled trial. Pharmacoeconomics 2002; 20: 61-70
14. Kobelt G, Lindgren P, Young A. Modelling the costs and effects of leflunomide in rheumatoid arthritis. Eur J Health Econ 2002; 3: 180-7
15. Maetzel A, Strand V, Tugwell P, et al. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res 2002; 47: 655-61
16. Schädlich PK, Zeidler H, Zink A, et al. Wirtschaftlichkeit von Leflunomid bei sequentieller Basistherapie der rheumatoiden Arthritis in Deutschland. Z Rheumatol 2004; 63: 59-75
17. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35
18. Alarcón GS, Tracy IC, Blackburn Jr WD. Methotrexate in rheumatoid arthritis: toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 1989; 32: 671-6
19. Buchbinder R, Hall S, Sambrook PN, et al. Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol 1993; 20: 639-44
20. De La Mata J, Blanco FJ, Gomez-Reino JJ. Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients. Ann Rheum Dis 1995; 54: 881-5
21. Jones E, Jones JV, Woodbury JF. Response to sulfasalazine in rheumatoid arthritis: life table analysis of a 5-year followup. J Rheumatol 1991; 18: 195-8
22. Morand EF, McCloud PI, Littlejohn GO. Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice. J Rheumatol 1992; 19: 704-8
23. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992; 19: 1885-94
24. Situnayake RD, Grindulis KA, McConkey B. Long-term treatment of rheumatoid arthritis with sulfasalazine, gold, or penicillamine: a comparison using life-table methods. Ann Rheum Dis 1987; 46: 177-83
25. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990; 17: 994-1002
26. Ramey DR, Raynauld JP, Fries JF. The health assessment questionnaire 1992: status and review. Arthritis Care Res 1992; 5: 119-29
27. Kobelt G, Eberhardt K, Jönnson L, et al. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999; 42: 347-56
28. The EuroQol Group. EuroQo1: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208
29. Felson DT, Anderson JJ, Chernoff MC, et al. The comparative efficacy of cyclosporine (CS) and other second line drugs in rheumatoid arthritis (RA): update of a meta-analysis [abstract]. Arthritis Rheum 1995; 38: S283
30. Brecht JG, Jenke A, Köhler ME, et al. Empfehlungen der Deutschen Gesellschaft für Klinische Phamakologie und Therapie e.V. zur Durchführung und Bewertung pharmakoökonomischer Studien. Med Klin 1995; 90: 541-6
31. Aventis Pharma Deutschland GmbH. Percentage of patients with improvement of 20%. 50%, and 70%, according to the American College of Rheumatology (ACR) criteria, over time treated with methotrexate or leflunomide in the US trial US301 and the international trial MN302: intention-to-treat population with last observation carried forward. Bad Soden/Taunus: Aventis Pharma Deutschland GmbH, 2001 Jul 3. (Data on file)
32. Bundesministerium für Gesundheit. Bekanntmachung des Bundesausschusses der Arzte und Krankenkassen - Änderung der Arzneimittel-Richtlinien. Vom 10. December 1999. BAnz 2000; 52: 5777
33. Raspe HH, Hagedorn U, Kohlmann T, et al. Der Funktionsfragebogen Hannover (FFbH): Ein Instrument zur Frühdiagnostik bei polyartikulären Gelenkerkrankungen. In: Siegrist J, editor. Wohnortnahe Betreuung Rheumakranker. Stuttgart: Schattauer, 1990: 164-182
34. Lautenschläger J, Mau W, Kohlmann T, et al. Vergleichende Evaluation einer deutschen Version des Health Assessment Questionnaires (HAQ) und des Funktionsfragebogens Hannover (FFbH). Z Rheumatol 1997; 56: 144-55
35. Zink A, Listing M, Niewerth H, et al. The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients. Ann Rheum Dis 2001; 60: 199-206
36. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24
37. Prevoo ML, van Riel PL, vant't Hof MA, et al. Validity and reliability of joint indices; a longitudinal study in patients with recent onset rheumatoid arthritis. Br J Rheumatol 1993; 32: 589-94
38. Prevoo ML, vant't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8
39. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. New York (NY): Oxford University Press, 1997
40. Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses. Rheumatology 2002; 41: 1367-74
41. L Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999; 42: 1209-18
42. Michaud K, Messer J, Choi H, et al. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum 2003; 48: 2750-62
43. Sokka T, Motionen T, Hannonen P. Disease-modifying anti-rheumatic drug use according to the 'sawtooth' treatment strategy improves the functional outcome in rheumatoid arthritis: results of a long-term follow-up study with review of the literature. Rheumatology 2000; 39: 34-42
44. Albert DA, Aksentijevich S, Hurst S, et al. Modeling therapeutic strategies in rheumatoid arthritis: use of decision analysis and Markov models. J Rheumatol 2000; 27: 644-52
45. Albers JMC, Paimela L, Kurki P, et al. Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis. Ann Rheum Dis 2001; 60: 453-8
46. Stenger AAME, van Leeuwen MA, Houtman PM, et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol 1998; 37: 1157-63
47. van der Heijde DM, van Leeuwen MA, van Riel PL, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992; 35: 26-34
48. Gabriel SE, Tugwell P, Drummond M. Progress towards on OMERCT-ILAR guideline for economic evaluations in rheumatology. Ann Rheum Dis 2002; 61: 370-3
49. Maetzel A, Tugwell P, Boers M, et al. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J Rheumatol 2003; 30: 891-6
50. Kroot EJA, van Leeuwen MA, van Rijswijk MH, et al. No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. Ann Rheum Dis 2000; 59: 954-8
51. Goodson NJ, Wiles NJ, Lunt M, et al. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002; 46: 2010-9
52. Hurst S, Kallan MJ, Wolfe FJ, et al. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects. J Rheumatol 2002; 29: 1639-45
53. Cohen S, Cannon GW, Schiff M, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate: utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001; 44: 1984-92
54. Schädlich PK, Brecht JG, Gromnica-Ihle E, et al. Effizienz von Leflunomid bei sequentieller Basistherapie von rheumatoider Arthritis in Deutschland [abstract P58]. Z Rheumatol 2002; 61 Suppl. 1:188